Immunologically, UDCA degrades TGF-β to inhibit Tregs differentiation and synergizes with anti-PD-1 by augmenting tumor-specific CD8+ T cell memory, correlating with improved objective response rates in retrospective cohorts [148]. This evidence concerns the gene PDCD1 and neoplasm.